Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)
CNY 8.87
(2.31%)
CNY 8.87
(2.31%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -98.34 Million CNY | 13.03% |
| 2022 | -113.08 Million CNY | -139.66% |
| 2021 | -47.18 Million CNY | -195.23% |
| 2020 | 49.55 Million CNY | 40.77% |
| 2019 | 35.19 Million CNY | 327.99% |
| 2018 | 8.22 Million CNY | 118.41% |
| 2017 | -44.68 Million CNY | -350.38% |
| 2016 | 17.84 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -25.6 Million CNY | 50.58% |
| 2024 Q2 | -44.8 Million CNY | -74.97% |
| 2024 Q3 | -42.29 Million CNY | 5.59% |
| 2023 Q2 | -13.18 Million CNY | -3685.05% |
| 2023 FY | -98.34 Million CNY | 13.03% |
| 2023 Q4 | -51.81 Million CNY | -88.99% |
| 2023 Q3 | -27.41 Million CNY | -107.91% |
| 2023 Q1 | 367.81 Thousand CNY | 100.8% |
| 2022 Q3 | -34.77 Million CNY | 20.59% |
| 2022 FY | -113.08 Million CNY | -139.66% |
| 2022 Q2 | -43.79 Million CNY | -47.79% |
| 2022 Q1 | -29.63 Million CNY | 39.18% |
| 2022 Q4 | -45.78 Million CNY | -31.65% |
| 2021 Q2 | 24.08 Thousand CNY | -99.8% |
| 2021 Q1 | 11.89 Million CNY | -26.55% |
| 2021 Q4 | -48.71 Million CNY | -591.73% |
| 2021 Q3 | -7.04 Million CNY | -29344.9% |
| 2021 FY | -47.18 Million CNY | -195.23% |
| 2020 Q2 | 24.79 Million CNY | 593.24% |
| 2020 Q1 | 3.57 Million CNY | -83.91% |
| 2020 FY | 49.55 Million CNY | 40.77% |
| 2020 Q4 | 16.19 Million CNY | 225.02% |
| 2020 Q3 | 4.98 Million CNY | -79.89% |
| 2019 Q4 | 22.22 Million CNY | 545.61% |
| 2019 Q2 | 11.19 Million CNY | 65.57% |
| 2019 Q1 | 6.76 Million CNY | 0.0% |
| 2019 FY | 35.19 Million CNY | 327.99% |
| 2019 Q3 | -4.98 Million CNY | -144.55% |
| 2018 FY | 8.22 Million CNY | 118.41% |
| 2017 FY | -44.68 Million CNY | -350.38% |
| 2016 FY | 17.84 Million CNY | 0.0% |